IN2015DN02993A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02993A
IN2015DN02993A IN2993DEN2015A IN2015DN02993A IN 2015DN02993 A IN2015DN02993 A IN 2015DN02993A IN 2993DEN2015 A IN2993DEN2015 A IN 2993DEN2015A IN 2015DN02993 A IN2015DN02993 A IN 2015DN02993A
Authority
IN
India
Prior art keywords
activity
subject
antibodies
enhance
amino acids
Prior art date
Application number
Inventor
Jason Marc Goldstein
Conrad P Quinn
Dennis A Bagarozzi
Applicable Not
Original Assignee
Centers Disease Control & Prevention
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centers Disease Control & Prevention filed Critical Centers Disease Control & Prevention
Publication of IN2015DN02993A publication Critical patent/IN2015DN02993A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24083—Anthrax lethal factor endopeptidase (3.4.24.83)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided are peptides capable of reducing the ability of antibodies to stimulate the activity of B. anthracis lethal factor. These peptides may be used to reduce activity of LF in a sample containing an LF activity enhancing antibody , to prevent the possibility of LF enhanced activity in a sample or subject, or as a therapeutic to reduce LF activity in a subject that may - have one or more antibodies that enhance LF activity. Also , provided are immunogens that may be used in a vaccine to confer protection to a subject. An immunogen does not include a sequence including the wild- type amino acids present in LF residues 677- 680 , or mutations of amino acids 677- 680 that will also generate antibodies that enhance LF activity.
IN2993DEN2015 2012-09-11 2013-09-11 IN2015DN02993A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699738P 2012-09-11 2012-09-11
PCT/US2013/059179 WO2014088664A2 (en) 2012-09-11 2013-09-11 Regulating bacillus anthracis lethal factor activity via an activating epitope region

Publications (1)

Publication Number Publication Date
IN2015DN02993A true IN2015DN02993A (en) 2015-09-25

Family

ID=50884117

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2993DEN2015 IN2015DN02993A (en) 2012-09-11 2013-09-11

Country Status (4)

Country Link
US (1) US20160039874A1 (en)
EP (1) EP2895857A4 (en)
IN (1) IN2015DN02993A (en)
WO (1) WO2014088664A2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176275B2 (en) * 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
WO2007145760A2 (en) * 2006-05-12 2007-12-21 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
US8362203B2 (en) * 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
EP2496597A4 (en) * 2009-11-06 2013-08-14 Childrens Hosp & Res Ct Oak T-cell stimulating protein b and methods of use
US20110214205A1 (en) * 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits

Also Published As

Publication number Publication date
WO2014088664A3 (en) 2014-10-16
US20160039874A1 (en) 2016-02-11
EP2895857A2 (en) 2015-07-22
WO2014088664A2 (en) 2014-06-12
EP2895857A4 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
PH12016500388A1 (en) Gitr antigen binding proteins
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
MX2019013123A (en) Oral dosing of glp-1 compounds.
NZ705370A (en) Fcγriib-specific fc region variant
TR201905619T4 (en) Peptide carrier fusion proteins as allergy vaccines.
NZ709059A (en) Immunotherapy with binding agents
IN2014KN03063A (en)
SG10201900727QA (en) Personalized immunotherapy against several neuronal and brain tumors
IN2014DN10288A (en)
MX348071B (en) Fc variants.
MX364689B (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
EA201591791A1 (en) MAN PAC1 ANTIBODIES
EA201491784A1 (en) Antibodies Against Ligand Recorder B1 Bradykinin
MX366178B (en) Human btnl3 proteins, nucleic acids, and antibodies and uses thereof.
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
EA201692279A1 (en) METHOD FOR REDUCING IMMUNOGENIC PROTEIN AND PEPTIDE
MA37749B1 (en) Vaccines against bluetongue and African horse sickness virus
EA201790680A1 (en) VACCINES AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) CONTAINING ONE OR MORE EPISENSUS (EPISENSUS) FOR POPULATION OF ANTIGENES
AR128395A2 (en) NOVEL PEPTIDES ABLE TO INDUCE THE FORMATION OF ANTIBODIES AGAINST PCSK9
EP2552462A4 (en) Ccn3 peptides and analogs thereof for therapeutic use